Abstract
Fragment screens for new ligands have had wide success, notwithstanding their constraint to libraries of 1,000–10,000 molecules. Larger libraries would be addressable were molecular docking reliable for fragment screens, but this has not been widely accepted. To investigate docking's ability to prioritize fragments, a library of >137,000 such molecules were docked against the structure of β-lactamase. Forty-eight fragments highly ranked by docking were acquired and tested; 23 had K i values ranging from 0.7 to 9.2 mM. X-ray crystal structures of the enzyme-bound complexes were determined for 8 of the fragments. For 4, the correspondence between the predicted and experimental structures was high (RMSD between 1.2 and 1.4 Å), whereas for another 2, the fidelity was lower but retained most key interactions (RMSD 2.4–2.6 Å). Two of the 8 fragments adopted very different poses in the active site owing to enzyme conformational changes. The 48% hit rate of the fragment docking compares very favorably with “lead-like” docking and high-throughput screening against the same enzyme. To understand this, we investigated the occurrence of the fragment scaffolds among larger, lead-like molecules. Approximately 1% of commercially available fragments contain these inhibitors whereas only 10 −7 % of lead-like molecules do. This suggests that many more chemotypes and combinations of chemotypes are present among fragments than are available among lead-like molecules, contributing to the higher hit rates. The ability of docking to prioritize these fragments suggests that the technique can be used to exploit the better chemotype coverage that exists at the fragment level.
References
28
Referenced
91
10.1021/jp952516o
10.1002/(SICI)1098-1128(199907)19:4<321::AID-MED5>3.0.CO;2-F
10.1038/nbt0596-595
- ML Verdonk, MJ Hartshorn, Structure-guided fragment screening for lead discovery. Curr Opin Drug Discov Dev 7, 404–410 (2004). / Curr Opin Drug Discov Dev / Structure-guided fragment screening for lead discovery by Verdonk ML (2004)
10.2174/156802607782341109
10.1007/BF00129424
10.1021/ci000403i
10.1021/ci600423u
10.1021/ci700342h
10.1021/ci049714
10.1016/S0169-409X(00)00129-0
10.1021/ci010366a
10.1021/jm061389p
10.1021/jm0209937
10.1023/B:JCAM.0000004604.87558.02
10.1016/S0969-2126(02)00799-2
10.1021/jm701500e
10.1158/1535-7163.MCT-05-0524
10.1021/jm050499d
10.1021/jm800382h
- RE Hubbard, I Chen, B Davis, Informatics and modeling challenges in fragment-based drug discovery. Curr Opin Drug Discovery Dev 10, 289–297 (2007). / Curr Opin Drug Discovery Dev / Informatics and modeling challenges in fragment-based drug discovery by Hubbard RE (2007)
10.1021/ja056806m
10.1016/S1359-6446(05)03511-7
10.1038/nchembio831
10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8
10.2174/1386207043328625
10.1021/ci010041u
10.1021/jm020002p
Dates
Type | When |
---|---|
Created | 16 years, 4 months ago (April 22, 2009, 8:55 p.m.) |
Deposited | 3 years, 4 months ago (April 12, 2022, 5:19 p.m.) |
Indexed | 1 year, 1 month ago (Aug. 5, 2024, 5:15 a.m.) |
Issued | 16 years, 4 months ago (May 5, 2009) |
Published | 16 years, 4 months ago (May 5, 2009) |
Published Online | 16 years, 4 months ago (May 5, 2009) |
Published Print | 16 years, 4 months ago (May 5, 2009) |
@article{Teotico_2009, title={Docking for fragment inhibitors of AmpC β-lactamase}, volume={106}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.0813029106}, DOI={10.1073/pnas.0813029106}, number={18}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Teotico, Denise G. and Babaoglu, Kerim and Rocklin, Gabriel J. and Ferreira, Rafaela S. and Giannetti, Anthony M. and Shoichet, Brian K.}, year={2009}, month=may, pages={7455–7460} }